ArticleFrontiers in cardiovascular medicine2025
Investigation of the effect of quercetin on experimental traumatic cardiac injury in rats.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the Nrf2-Keap1 Pathway in Patients with Acute Cerebral Ischemic Disease.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardioprotection is an important aspect of preventive medicine. Quercetin, a plant-derived flavonoid with antioxidant and anti-inflammatory properties, has been linked to reduced cardiovascular risk. Objective: To investigate the cardioprotective effects of quercetin in rats with traumatic cardiac injury (TCI). Methods: Fifty-two Wistar Albino rats were randomly divided into six groups: control ( Results: GPx elevation was detected only at 10 and 20 mg/kg (vs. TCI; Conclusions: Quercetin, especially at 40 mg/kg, may help prevent secondary cardiac injury after trauma by reducing oxidative stress and limiting histopathological damage. These results support quercetin's cardioprotective potential and warrant confirmation in larger preclinical models with broader designs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.